NCT07335796

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

A Phase 2 Study of Androgen Deprivation Therapy and BMS986365 in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	BMS-986165	BMS986365 (CC-94676) is an androgen receptor (AR) ligand-directed degrader that was designed to target the AR for degradation in castration-resistant prostate cancer (CRPC)
DRUG	Degarelix	Degarelix is a GnRH antagonist that blocks the action of GnRH on the pituitary and effectively suppresses testosterone production

Timeline

• Start date: 2026-01-09
• Primary completion: 2030-01-09
• Completion: 2030-01-09
• First posted: 2026-01-13
• Last updated: 2026-03-13

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study